This is a relevant finding as the lack of c-kit mutations in a tumor does not imply a lack of responsiveness to TKI treatment as long as CD117 is expressed, which suggests the involvement of alternative mechanisms in CD117 activation and response to TKI treatments. Here, KIT is linked to neoplasm.